Alembic Pharmaceuticals Limited (APLLTD.BO)
INR 850.0
(0.7%)
INR 850.0
(0.7%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 628.8 Million INR | -9.17% |
| 2022 | 692.3 Million INR | -4.03% |
| 2021 | 721.4 Million INR | -73.42% |
| 2020 | 2.71 Billion INR | -71.73% |
| 2019 | 9.6 Billion INR | 92.33% |
| 2018 | 4.99 Billion INR | -0.14% |
| 2017 | 5 Billion INR | 0.0% |
| 2016 | - INR | 0.0% |
| 2015 | - INR | -100.0% |
| 2014 | 188 Million INR | -64.0% |
| 2013 | 522.2 Million INR | -25.97% |
| 2012 | 705.34 Million INR | -25.64% |
| 2011 | 948.56 Million INR | -26.17% |
| 2010 | 1.28 Billion INR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 Q1 | - INR | -100.0% |
| 2023 FY | 628.8 Million INR | -9.17% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q4 | 628.8 Million INR | 0.0% |
| 2023 Q2 | 674.1 Million INR | 0.0% |
| 2022 Q4 | 692.3 Million INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 FY | 692.3 Million INR | -4.03% |
| 2022 Q2 | 617.5 Million INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 FY | 721.4 Million INR | -73.42% |
| 2021 Q4 | 721.4 Million INR | 0.0% |
| 2021 Q2 | 776.5 Million INR | 0.0% |
| 2020 Q4 | 2.71 Billion INR | 0.0% |
| 2020 FY | 2.71 Billion INR | -71.73% |
| 2020 Q2 | 5.99 Billion INR | 0.0% |
| 2019 Q2 | 7.86 Billion INR | 0.0% |
| 2019 Q4 | 9.6 Billion INR | 0.0% |
| 2019 FY | 9.6 Billion INR | 92.33% |
| 2018 FY | 4.99 Billion INR | -0.14% |
| 2018 Q4 | 4.99 Billion INR | 0.0% |
| 2018 Q2 | 5 Billion INR | 0.0% |
| 2017 Q4 | 5 Billion INR | 0.0% |
| 2017 Q2 | 2.85 Billion INR | 0.0% |
| 2017 FY | 5 Billion INR | 0.0% |
| 2016 Q4 | - INR | 0.0% |
| 2016 FY | - INR | 0.0% |
| 2016 Q2 | - INR | 0.0% |
| 2015 FY | - INR | -100.0% |
| 2015 Q2 | 66.2 Million INR | 0.0% |
| 2015 Q4 | - INR | 0.0% |
| 2014 Q4 | 188 Million INR | 0.0% |
| 2014 FY | 188 Million INR | -64.0% |
| 2014 Q2 | 309.2 Million INR | 0.0% |
| 2013 Q4 | 522.2 Million INR | 0.0% |
| 2013 FY | 522.2 Million INR | -25.97% |
| 2013 Q2 | 715.5 Million INR | 0.0% |
| 2012 Q2 | 1.62 Billion INR | 0.0% |
| 2012 FY | 705.34 Million INR | -25.64% |
| 2012 Q4 | 705.34 Million INR | 0.0% |
| 2011 FY | 948.56 Million INR | -26.17% |
| 2010 FY | 1.28 Billion INR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Aurobindo Pharma Limited | 21.34 Billion INR | 97.055% |
| Glenmark Life Sciences Limited | 147.61 Million INR | -325.987% |
| Granules India Limited | 689.71 Million INR | 8.831% |
| Indoco Remedies Limited | 3.51 Billion INR | 82.123% |
| Achyut Healthcare Limited | - INR | -Infinity% |
| Ajanta Pharma Limited | 235.2 Million INR | -167.347% |
| Alkem Laboratories Limited | 400 Million INR | -57.2% |
| Alpa Laboratories Limited | - INR | -Infinity% |
| Brooks Laboratories Limited | 3.56 Million INR | -17538.149% |
| AstraZeneca Pharma India Limited | 27.83 Million INR | -2158.945% |
| Bajaj HealthCare Limited | 650.34 Million INR | 3.313% |
| Bliss GVS Pharma Limited | 355.92 Million INR | -76.668% |
| Dr. Reddy's Laboratories Limited | 5.99 Billion INR | 89.503% |
| Eris Lifesciences Limited | 6.54 Billion INR | 90.393% |
| FDC Limited | 2.46 Million INR | -25398.783% |
| Glenmark Pharmaceuticals Limited | 1.51 Billion INR | 58.547% |
| Gufic Biosciences Limited | 1.53 Billion INR | 59.159% |
| Ind-Swift Laboratories Limited | 111.62 Million INR | -463.31% |
| Ipca Laboratories Limited | 5.8 Billion INR | 89.166% |
| Jagsonpal Pharmaceuticals Limited | 75.57 Million INR | -732.076% |
| Krebs Biochemicals & Industries Limited | 1.83 Billion INR | 65.733% |
| Lasa Supergenerics Limited | - INR | -Infinity% |
| Laurus Labs Limited | 8.6 Billion INR | 92.692% |
| Lupin Limited | 1.55 Billion INR | 59.505% |
| Mankind Pharma Limited | 248.67 Million INR | -152.858% |
| Medicamen Biotech Limited | 12.55 Million INR | -4908.363% |
| Medico Remedies Limited | 8.67 Million INR | -7150.923% |
| Megasoft Limited | 1.35 Billion INR | 53.665% |
| NATCO Pharma Limited | 53 Million INR | -1086.415% |
| Piramal Pharma Limited | 24.83 Billion INR | 97.468% |
| RPG Life Sciences Limited | -30.3 Million INR | 2175.248% |
| Sigachi Industries Limited | 265.79 Million INR | -136.571% |
| Sun Pharmaceutical Industries Limited | 13.3 Million INR | -4627.82% |
| Suven Pharmaceuticals Limited | 212.35 Million INR | -196.107% |
| Syncom Formulations (India) Limited | -1.21 Million INR | 51683.265% |
| Unichem Laboratories Limited | 382.22 Million INR | -64.512% |
| Wanbury Limited | 820 Million INR | 23.317% |
| Windlas Biotech Limited | 20.18 Million INR | -3015.956% |
| ZIM Laboratories Limited | 356 Million INR | -76.626% |
| Zydus Lifesciences Limited | 251 Million INR | -150.518% |
| Sun Pharma Advanced Research Company Limited | 106.6 Million INR | -489.869% |
| Divi's Laboratories Limited | 20 Million INR | -3044.0% |
| Hester Biosciences Limited | 1.81 Billion INR | 65.407% |
| Procter & Gamble Health Limited | 68.8 Million INR | -813.953% |
| Amrutanjan Health Care Limited | 13.96 Million INR | -4401.718% |
| Bal Pharma Limited | 363.82 Million INR | -72.831% |
| Strides Pharma Science Limited | 6.71 Billion INR | 90.636% |
| Venus Remedies Limited | 386.8 Million INR | -62.565% |
| Aarti Pharmalabs Limited | 400 Thousand INR | -157100.0% |
| Nectar Lifesciences Limited | 1.4 Billion INR | 55.185% |
| Shilpa Medicare Limited | 5.6 Billion INR | 88.775% |
| Aarti Drugs Limited | 2.75 Billion INR | 77.162% |
| IOL Chemicals and Pharmaceuticals Limited | - INR | -Infinity% |
| Suven Life Sciences Limited | - INR | -Infinity% |
| Ind-Swift Limited | 10.09 Billion INR | 93.771% |
| Valiant Laboratories Limited | 746.63 Million INR | 15.782% |
| J. B. Chemicals & Pharmaceuticals Limited | 236.4 Million INR | -165.99% |
| Solara Active Pharma Sciences Limited | 1.05 Billion INR | 40.584% |
| Themis Medicare Limited | 267.74 Million INR | -134.855% |
| Hikal Limited | 4.22 Billion INR | 85.129% |
| Torrent Pharmaceuticals Limited | 16.04 Billion INR | 96.08% |
| Sequent Scientific Limited | 1.42 Billion INR | 55.941% |
| Novartis India Limited | 50.7 Million INR | -1140.237% |
| Wockhardt Limited | 8.91 Billion INR | 92.943% |
| Jubilant Pharmova Limited | 31.67 Billion INR | 98.015% |
| Biofil Chemicals and Pharmaceuticals Limited | - INR | -Infinity% |
| Neuland Laboratories Limited | 449.2 Million INR | -39.98% |
| Morepen Laboratories Limited | 33.64 Million INR | -1769.203% |
| Kilitch Drugs (India) Limited | - INR | -Infinity% |
| Mangalam Drugs & Organics Limited | 133.54 Million INR | -370.867% |